Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO

• Status: Unknown status
• Trial end date: 2019-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the efficiency of ICS(budesonide) combined with LABA (formoterol) and LAMA(tiotropium) in the treatment of acute exacerbation of asthma-chronic obstructive pulmonary overlap. Half of participants will receive budesonide,formoterol and tiotropium in combination, while the other half will receive budesonide and formoterol only.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huashan Hospital
• Treatments: Bromides; Budesonide; Formoterol Fumarate; Tiotropium Bromide

Criteria

Inclusion Criteria:

• subject has ACO

Exclusion Criteria:

• acute exacerbation of ACO;

• acute infection;

• postbrochodilator FEV1/FVC> 0.7;

• pulmonary complications: bronchiectasis, active tuberculosis, pulmonary fungal disease or lung cancer

• history of other malignant tumor

• with rheumatic diseases;

• with some serious heart, cerebrovascular, liver, kidney or hematopoietic system diseases

• with tachyarrhythmias；

• mental patients;

• with moderate to severe renal insufficiency (creatinine clearance ≤ 50ml / h)

• allergic to the budesonide, formoterol or tiotropium bromide;

• history of acute gastrointestinal bleeding within 3 months;

• with severe angle closure glaucoma patients;

• pregnancy,lactation;

• have participated in other clinical trials in 3 months；

• hospital staff and their relatives